News

Home>News
News2020-07-17T11:41:26-04:00
Nov 222021

Halberd Successfully Eradicates TNF-α, a Major Contributing Factor to Alzheimer’s Disease

November 22nd, 2021|Categories: Investor News, News, Press Releases|Tags: , , , , , , , , , , , , |

Halberd Successfully Eradicates TNF-α, a Major Contributing Factor to Alzheimer’s Disease Jackson Center, PA, November 22, 2021 – Halberd Corporation (OTC PINK:HALB) successfully eradicated 85% of Tumor Necrosis Factor-alpha (TNF-α) from synthetic cerebral spinal fluid (CSF) in preliminary testing.  Through Halberd’s patented extracorporeal process, in combination with its patent-pending laser eradication methodology, TNF-α was eliminated through exposure to tuned laser irradiation.  TNF-α is an inflammatory cytokine which has been identified as a major contributor to ...

Nov 82021

Halberd Files Additional Extracorporeal Patent Application: Treatment of Covid-19 By Exposure to Tuned Radio Frequency Waves

November 8th, 2021|Categories: Featured, Investor News, News, Press Releases|Tags: , , , , , , , , , |

Jackson Center, PA, November 8, 2021 – Halberd Corporation (OTC-PINK: "HALB") filed a non-provisional patent application for the extracorporeal treatment of Covid-19 through exposure to radio frequency waves.  Previously, Halberd filed a provisional patent application on this treatment method.  Halberd believes this treatment would be effective against all SARS-CoV-2 variants, and this application preserves Halberd’s intellectual property rights.  Halberd works to continue to perfect this underlying extracorporeal treatment process on neurodegenerative diseases. The continuous flow ...

Nov 12021

Halberd Successfully Eradicates IL-6, a Critical Factor in PTSD, CTE & Alzheimer’s Disease

November 1st, 2021|Categories: Featured, Investor News, Medical, News|Tags: , , , , , , , , , , , , |

Elevated levels of IL-6 are believed to be causal factors in PTSD, Chronic Traumatic Encephalopathy, & Alzheimer’s Disease. Jackson Center, PA, November 1, 2021 – Halberd Corporation (OTC PINK:HALB) successfully eradicated 100% of IL-6 from synthetic cerebral spinal fluid (CSF) in preliminary testing.  Through its patented extracorporeal process in combination with its patent-pending laser eradication process, IL-6 was virtually eliminated in as little as three minutes of laser radiation exposure.  Elevated levels of IL-6 in ...

Oct 252021

Halberd Files Provisional Patent on Breakthrough Obesity Treatment

October 25th, 2021|Categories: Featured, Investor News, Medical, News|Tags: , , , , , , , , |

Jackson Center, PA, October 25, 2021 – Halberd Corporation (OTC-PINK: HALB) announces the filing of a provisional patent application with the US Patent and Trademark Office covering their extracorporeal removal from the blood of patients of the various proteins, cytokines and antigens associated with obesity.  Removal of these obesity-related target elements would reduce or eliminate the negative health issues associated with obesity. Halberd’s researchers have discovered certain inflammatory cytokines associated with PTSD and Alzheimer’s Disease ...

Oct 202021

Halberd’s PTSD/Alzheimer’s R&D Reveals Link to Potential Obesity Cure

October 20th, 2021|Categories: Featured, Investor News, Medical, News|Tags: , , , , , , , |

Jackson Center, PA, October 20, 2021 – Halberd Corporation’s (OTC-PINK: HALB) ongoing research into discovering treatments/cures for PTSD, Alzheimer’s Disease, and other neurodegenerative diseases has led to a potential breakthrough in the battle against obesity.  Research has indicated inflammatory cytokines present in the Cerebral Spinal Fluid (CSF) of neurodegenerative disease patients are also found in the blood of those suffering from obesity. Halberd’s patent-pending extracorporeal treatment for removing the disease antigens, excess proteins and cytokines ...

Oct 192021

Interleukin-6 induces impairment in human subcutaneous adipogenesis in obesity-associated insulin resistance

October 19th, 2021|Categories: Press Releases|

Abstract Aims/hypothesis A subset of obese individuals remains insulin sensitive by mechanisms as yet unclear. The hypothesis that maintenance of normal subcutaneous (SC) adipogenesis accounts, at least partially, for this protective phenotype and whether it can be abrogated by chronic exposure to IL-6 was investigated. Methods Adipose tissue biopsies were collected from insulin-sensitive (IS) and insulin-resistant (IR) individuals undergoing weight-reduction surgery. Adipocyte size, pre-adipocyte proportion of stromal vascular fraction (SVF)-derived cells, adipogenic capacity and gene ...

Go to Top